Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Multicenter, Open Label, Dose Escalation & Dose Expansion Study of JK08, an IL-15 Antibody Fusion Protein Targeting CTLA-4, Monotherapy or in Combination in Patients with Unresectable Locally Advanced or Metastatic Cancer

NCT05620134 is registered in ClinicalTrials.gov with Salubris Biotherapeutics Inc as lead sponsor.

NCT NCT05620134
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05620134 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Multicenter, Open Label, Dose Escalation & Dose Expansion Study of JK08, an IL-15 Antibody Fusion Protein Targeting CTLA-4, Monotherapy or in Combination in Patients with Unresectable Locally Advanced or Metastatic Cancer
Lead sponsor
Salubris Biotherapeutics Inc
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
October 17, 2022
Completion date
February 20, 2026
Enrollment
263 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, cancer, clear cell renal cell carcinoma, colorectal adenocarcinoma, colorectal cancer, epithelial ovarian cancer, gastric adenocarcinoma, gastroesophageal cancer, hepatocellular carcinoma, luminal breast cancer, melanoma, metastatic cancer, non-small cell lung cancer, pancreatic adenocarcinoma, papillary renal cell carcinoma, small-cell lung cancer, squamous cell carcinoma of head and neck, squamous cell carcinoma skin, thyroid cancer, triple negative breast cancer, tumor, solid, urothelial carcinoma